Table 2.
Group | Evidence type | Type of information | Percentage (%)* |
---|---|---|---|
A | Sign or symptom | Outcome | 100.0 |
B | Tdap | Cause | 65.6 |
C | Vaccine or vaccination | Cause | 64.0 |
D | Injection site or injection without non-Tdap terms | Spatial (location) and cause | 60.0 |
E | Local reaction (explicitly stated) | Spatial (location) and cause | 10.4 |
F | Vaccine site | Spatial (location) and cause | 8.8 |
G | Tdap site such as “Tdap location” | Spatial (location) and cause | 35.2 |
H | Sign or symptom occurred with the vaccine site | Spatial (location) and outcome | 89.6 |
I | Vaccine reaction | Cause and outcome | 31.2 |
J | Sign or symptom was caused by something other than Tdap | Cause | 0 |
Percentages in NLP positive cases among the validation data.